Latest Peptide News
Peptide News — page 2
Enobosarm GLP-1 Trial: 239-Patient Muscle Study Closes Enrollment
A ClinicalTrials.gov update dated September 4, 2026 shows the enobosarm GLP-1 trial has finished enrolling 239 participants and moved into its active, non-recruiting phase. It is one of the clearest signals yet that drug development around incretin therapy has shifted from how much weight comes off to what tissue comes off with it.
Stopping and Restarting Tirzepatide Gets Its Own Clinical Trial
Registry records updated in early September 2026 show researchers are now studying stopping and restarting tirzepatide as a deliberate, measured event rather than an accident of insurance or supply. A separate Phase 3a trial is testing early semaglutide re-initiation after bariatric surgery in adolescents.
CagriSema vs Tirzepatide Trial Completes in Type 2 Diabetes
A phase 3 CagriSema vs tirzepatide trial in more than a thousand adults with type 2 diabetes has moved to completed status on the federal trial registry, setting up the first direct comparison between Novo Nordisk's investigational amylin-GLP-1 combination and Eli Lilly's approved dual agonist. Two separate phase 3 trials of cagrilintide on its own also appeared in the same registry update.
Semaglutide Lifespan Mice Study: What the Nature Paper Actually Found
A semaglutide lifespan mice study published in Nature reports that older female mice given the GLP-1 drug lived longer and scored better on health measures than untreated animals. The National Institutes of Health says the effect went beyond what calorie restriction alone produced — a claim that will shape how the drug class is discussed for years, and one that arrives the same week European regulators fined news outlets for over-enthusiastic GLP-1 coverage.
FDA Unapproved GLP-1 Drugs Alert: What the Agency Is Warning About
The FDA refreshed its standing alert on unapproved GLP-1 drugs used for weight loss on September 1, 2026, restating why products sourced outside the approved supply chain carry risks the agency cannot vouch for. For anyone tracking a semaglutide or tirzepatide protocol, the practical question is where the product came from and what is actually on the label.
Weight Regain After Stopping Semaglutide Mapped in New Meta-Analysis
A reconstructed aggregate-data meta-analysis published in Endocrinology, Diabetes & Metabolism models weight regain after stopping semaglutide or tirzepatide, and it landed the same week as a separate analysis of glycaemic changes after semaglutide discontinuation in type 1 diabetes. Together they sharpen a question that matters to anyone on a GLP-1 protocol: what happens when the injections stop.
CagriSema Phase 3 Trials Expand Into Children and a New Dose Comparison
ClinicalTrials.gov records reviewed on August 31, 2026 show the CagriSema phase 3 trials program has widened to include adolescents and a head-to-head comparison of two CagriSema dose levels against semaglutide alone. For anyone already tracking a semaglutide protocol, this is the clearest signal yet of what the next generation of injectable obesity medicines is being tested to do.
Retatrutide Diabetic Ketoacidosis Case Report Involves Online Source
A single-patient report newly indexed in PubMed describes retatrutide diabetic ketoacidosis risk in a type 1 diabetes patient who bought the investigational drug online while also fighting a bacterial gut infection. It is the kind of case that surfaces when an unapproved molecule circulates faster than its clinical evidence.
Semaglutide heart effects: new cardiac CT and tissue studies
A cluster of new peer-reviewed publications shifts attention from weight and glucose toward semaglutide heart effects — specifically cardiac structure, gene expression in human heart tissue, and cardiovascular outcomes in people with diabetes and existing vascular or kidney disease. None of them changes how anyone takes the drug, but together they show where the research is heading.
Semaglutide Opioid Use Disorder Trial Opens Phase 2 Enrollment
A Phase 2 semaglutide opioid use disorder trial is now recruiting 200 adults in outpatient addiction treatment, testing whether the GLP-1 receptor agonist helps people refrain from illicit opioids. It is one of two new GLP-1 trials registered this week that push these drugs well outside diabetes and weight management.
Semaglutide Muscle Loss Study Joins New Trials on Lean Mass
Three separate research entries indexed in the past week — a longitudinal semaglutide muscle loss study, a review of skeletal muscle health during incretin-based therapy, and a newly posted Phase 4 trial — all converge on the same unanswered question. For anyone tracking a GLP-1 protocol, lean mass is moving from forum speculation to formal endpoint.
Synthetic Semaglutide Claims Challenged Over Reporting Gaps
A newly indexed letter in Diabetes, Obesity & Metabolism takes aim at the evidence behind synthetic semaglutide used for weight management, arguing that reporting gaps make the clinical claims hard to evaluate. For anyone tracking a compounded or non-brand GLP-1 protocol, the argument is about what you can and cannot infer from a study that says the molecule is the same.